Tahlia Scheinberg

Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14).

Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14).

Journal: European urology oncology
Published: January 18, 2026

Immunotherapy in metastatic prostate cancer.

Immunotherapy in metastatic prostate cancer.

Journal: Therapeutic advances in medical oncology
Published: February 17, 2025

Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells.

Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells.

Journal: EBioMedicine
Published: January 22, 2025

Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304).

Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 16, 2024

Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy.

Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy.

Journal: Therapeutic advances in medical oncology
Published: September 09, 2024

An Australian mainstream genetic testing program: Clinicians views about current and future practices.

An Australian mainstream genetic testing program: Clinicians views about current and future practices.

Journal: Asia-Pacific journal of clinical oncology
Published: May 29, 2023

PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer.

PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer.

Journal: Prostate cancer and prostatic diseases
Published: November 15, 2022

Targeting lipid metabolism in metastatic prostate cancer.

Targeting lipid metabolism in metastatic prostate cancer.

Journal: Therapeutic advances in medical oncology
Published: August 25, 2022

Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin.

Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin.

Journal: Cancers
Published: August 22, 2022

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.

Journal: EBioMedicine
Published: September 05, 2021

Catastrophic chemotherapy toxicity leading to diagnosis of Fanconi anaemia due to FANCD1/BRCA2 during adulthood: description of an emerging phenotype.

Catastrophic chemotherapy toxicity leading to diagnosis of Fanconi anaemia due to FANCD1/BRCA2 during adulthood: description of an emerging phenotype.

Journal: Journal of medical genetics
Published: July 01, 2021

Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer.

Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer.

Journal: Asia-Pacific journal of clinical oncology
Published: June 20, 2021
Showing 1-12 of 16

Last Updated: 09/26/2026